Brief: Data From Phase 1B Trial With Ino-4201 As An Ebola Booster For Rvsv-Zebov (Ervebo®) Presented At Eccmid 2023

Inovio Pharmaceuticals

17/04/2023 13:07

April 17 (Reuters) - Inovio Pharmaceuticals Inc  INO.O :
    * DATA FROM PHASE 1B TRIAL WITH INO-4201 AS AN EBOLA BOOSTER
FOR
RVSV-ZEBOV (ERVEBO®) PRESENTED AT ECCMID 2023
    * INOVIO PHARMACEUTICALS INC: PRELIMINARY DATA SHOWED THAT
INO-4201 WAS WELL TOLERATED AND PRODUCED A STRONG IMMUNE
RESPONSE
    * INOVIO PHARMACEUTICALS INC:DATA SUGGESTS THAT A BOOSTER
DOSE OF
IN0-4201 HAS POTENTIAL TO EXTEND PROTECTION AGAINST EBOLA
    * INOVIO PHARMACEUTICALS INC: FULL DATA SET WAS PRESENTED AT
ECCMID, INCLUDING NEW HUMORAL AND CELLULAR RESPONSE DATA
    * INOVIO: DATA INDICATES POTENTIAL OF INO-4201 TO RESTORE
ANTIBODY
TITERS TO LEVELS THOUGHT TO BE REQUIRED TO PROVIDE PROTECTION
AGAINST ZAIRE EBOLAVIRUS

Source text for Eikon:  ID:nPn7D848wa 
Further company coverage:  INO.O